Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Karanikas, Chrisanthi A.
Funding for this research was provided by:
Eli Lilly and Company
12 August 2019
11 October 2019